Cargando…
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since t...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497728/ https://www.ncbi.nlm.nih.gov/pubmed/31080803 http://dx.doi.org/10.3389/fmed.2019.00086 |
_version_ | 1783415518030462976 |
---|---|
author | Fujimura, Taku Sato, Yota Tanita, Kayo Lyu, Chunbing Kambayashi, Yumi Amagai, Ryo Otsuka, Atsushi Fujisawa, Yasuhiro Yoshino, Koji Matsushita, Shigeto Uchi, Hiroshi Yamamoto, Yuki Hata, Hiroo Funakoshi, Takeru Nonomura, Yumi Tanaka, Ryota Okuhira, Hisako Wada, Naoko Hashimoto, Akira Aiba, Setsuya |
author_facet | Fujimura, Taku Sato, Yota Tanita, Kayo Lyu, Chunbing Kambayashi, Yumi Amagai, Ryo Otsuka, Atsushi Fujisawa, Yasuhiro Yoshino, Koji Matsushita, Shigeto Uchi, Hiroshi Yamamoto, Yuki Hata, Hiroo Funakoshi, Takeru Nonomura, Yumi Tanaka, Ryota Okuhira, Hisako Wada, Naoko Hashimoto, Akira Aiba, Setsuya |
author_sort | Fujimura, Taku |
collection | PubMed |
description | Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly higher in responders than in non-responders. In contrast, there were no significant differences in baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy. |
format | Online Article Text |
id | pubmed-6497728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64977282019-05-10 Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma Fujimura, Taku Sato, Yota Tanita, Kayo Lyu, Chunbing Kambayashi, Yumi Amagai, Ryo Otsuka, Atsushi Fujisawa, Yasuhiro Yoshino, Koji Matsushita, Shigeto Uchi, Hiroshi Yamamoto, Yuki Hata, Hiroo Funakoshi, Takeru Nonomura, Yumi Tanaka, Ryota Okuhira, Hisako Wada, Naoko Hashimoto, Akira Aiba, Setsuya Front Med (Lausanne) Medicine Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly higher in responders than in non-responders. In contrast, there were no significant differences in baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy. Frontiers Media S.A. 2019-04-26 /pmc/articles/PMC6497728/ /pubmed/31080803 http://dx.doi.org/10.3389/fmed.2019.00086 Text en Copyright © 2019 Fujimura, Sato, Tanita, Lyu, Kambayashi, Amagai, Otsuka, Fujisawa, Yoshino, Matsushita, Uchi, Yamamoto, Hata, Funakoshi, Nonomura, Tanaka, Okuhira, Wada, Hashimoto and Aiba. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Fujimura, Taku Sato, Yota Tanita, Kayo Lyu, Chunbing Kambayashi, Yumi Amagai, Ryo Otsuka, Atsushi Fujisawa, Yasuhiro Yoshino, Koji Matsushita, Shigeto Uchi, Hiroshi Yamamoto, Yuki Hata, Hiroo Funakoshi, Takeru Nonomura, Yumi Tanaka, Ryota Okuhira, Hisako Wada, Naoko Hashimoto, Akira Aiba, Setsuya Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title_full | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title_fullStr | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title_full_unstemmed | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title_short | Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma |
title_sort | association of baseline serum levels of cxcl5 with the efficacy of nivolumab in advanced melanoma |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497728/ https://www.ncbi.nlm.nih.gov/pubmed/31080803 http://dx.doi.org/10.3389/fmed.2019.00086 |
work_keys_str_mv | AT fujimurataku associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT satoyota associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT tanitakayo associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT lyuchunbing associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT kambayashiyumi associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT amagairyo associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT otsukaatsushi associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT fujisawayasuhiro associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT yoshinokoji associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT matsushitashigeto associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT uchihiroshi associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT yamamotoyuki associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT hatahiroo associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT funakoshitakeru associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT nonomurayumi associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT tanakaryota associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT okuhirahisako associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT wadanaoko associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT hashimotoakira associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma AT aibasetsuya associationofbaselineserumlevelsofcxcl5withtheefficacyofnivolumabinadvancedmelanoma |